TY - JOUR
T1 - Coronary vasoconstrictor response to cold pressor test in variant angina
T2 - Lack of relation to intracoronary thromboxane concentrations
AU - De Servi, Stefano
AU - Ferrario, Maurizio
AU - Rondanelli, Renato
AU - Corsico, Giovanna
AU - Poma, Ercole
AU - Ghio, Stefano
AU - Mussini, Antonio
AU - Angoli, Luigi
AU - Bramucci, Ezio
AU - Bré, Elena
AU - Specchia, Giuseppe
PY - 1987
Y1 - 1987
N2 - To test the hypothesis that intracoronary concentrations of thromboxane (Tx)A2 could influence the response to cold pressor test (CPT) in variant angina, great cardiac vein blood flow (by thermodilution) and the concentration of TxB2 (the stable metabolite of TxA2) in the great cardiac vein and aorta were measured under control conditions and during CPT in 14 patients with angina at rest associated with transient ST-segment elevation in the anterior leads. In seven patients pretreated with aspirin (intravenous administration of 3.6 mg/kg lysine salt of acetylsalicylic acid, corresponding to 2 mg/kg aspirin), TxB2 baseline concentrations were lower in both the great cardiac vein (47 ± 19 vs 176 ± 88 pg/ml; p <0.005) and the aorta (45 ± 16 vs 109 ± 56 pg/ml, p <0.02) than in seven patients who were not taking cyclooxygenase inhibitors. In the two groups, great cardiac vein flow and anterior region coronary resistance were similar under control conditions. During CPT anterior region coronary resistance increased in patients pretreated with aspirin (from 1.97 ± 0.99 to 2.22 ± 1.11 mm Hg/ml/min; p <0.02) and in patients without aspirin pretreatment (from 1.94 ± 0.43 to 2.06 ± 0.34 mm Hg/ml/min; p <0.05), and the difference between the two groups was not statistically significant. Therefore the vasoconstrictor response of coronary vessels to CPT in variant angina is not influenced by the intracoronary TxB2 concentrations and is not modified by aspirin pretreatment.
AB - To test the hypothesis that intracoronary concentrations of thromboxane (Tx)A2 could influence the response to cold pressor test (CPT) in variant angina, great cardiac vein blood flow (by thermodilution) and the concentration of TxB2 (the stable metabolite of TxA2) in the great cardiac vein and aorta were measured under control conditions and during CPT in 14 patients with angina at rest associated with transient ST-segment elevation in the anterior leads. In seven patients pretreated with aspirin (intravenous administration of 3.6 mg/kg lysine salt of acetylsalicylic acid, corresponding to 2 mg/kg aspirin), TxB2 baseline concentrations were lower in both the great cardiac vein (47 ± 19 vs 176 ± 88 pg/ml; p <0.005) and the aorta (45 ± 16 vs 109 ± 56 pg/ml, p <0.02) than in seven patients who were not taking cyclooxygenase inhibitors. In the two groups, great cardiac vein flow and anterior region coronary resistance were similar under control conditions. During CPT anterior region coronary resistance increased in patients pretreated with aspirin (from 1.97 ± 0.99 to 2.22 ± 1.11 mm Hg/ml/min; p <0.02) and in patients without aspirin pretreatment (from 1.94 ± 0.43 to 2.06 ± 0.34 mm Hg/ml/min; p <0.05), and the difference between the two groups was not statistically significant. Therefore the vasoconstrictor response of coronary vessels to CPT in variant angina is not influenced by the intracoronary TxB2 concentrations and is not modified by aspirin pretreatment.
UR - http://www.scopus.com/inward/record.url?scp=0023224638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023224638&partnerID=8YFLogxK
U2 - 10.1016/0002-8703(87)90746-0
DO - 10.1016/0002-8703(87)90746-0
M3 - Article
C2 - 3630891
AN - SCOPUS:0023224638
SN - 0002-8703
VL - 114
SP - 511
EP - 515
JO - American Heart Journal
JF - American Heart Journal
IS - 3
ER -